VectivBio Holding AG

VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the development of treatments for severe rare conditions with significant unmet medical need. Its product pipeline include Apraglutide and CoMet. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland.

VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland.

•  Treatment with apraglutide resulted in an average 50% reduction in Parenteral Support (PS) volume at six months

VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)

BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the date of the Extraordinary General Meeting, which will be held on Friday, December 9, 2022, at 10:00 a.m. CEST / 4:00 a.m. EDT at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland.

VectivBio Announces Date of Extraordinary General Meeting of Shareholders

BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced public offering of 6,467,688 ordinary shares, including the sale to the underwriters of 752,688 ordinary shares sold pursuant to the partial exercise of the underwriters' previously granted option to purchase additional ordinary shares and its previously announced private placement for the sale of 3,478,260 ordinary shares to Forbion's Growth Opportunities Fund II. All ordinary shares sold in the public offering were offered by VectivBio at a public offering price of $5.25 per share. The total gross proceeds to VectivBio from the public offering, including pursuant to the underwriters' option, were approximately $34 million, before deducting underwriting discounts and commissions and offering expenses. All ordinary shares sold in the private placement transaction were offered by VectivBio at a price of $5.75 per ordinary share, for gross proceeds to VectivBio of approximately $20 million, before deducting financial advisory fees and other offering expenses.

VectivBio Announces Closing of $54 Million Aggregate Financing

Combined Gross Proceeds from Public Offering and Private Sale Total $50 Million Combined Gross Proceeds from Public Offering and Private Sale Total $50 Million

VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares

BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the launch of a follow-on public offering of its ordinary shares. In addition, VectivBio expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares to be sold in the offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. All of the ordinary shares in the offering are to be sold by VectivBio.

VectivBio Announces Launch of Public Offering of Ordinary Shares

– Interim proof-of-concept data anticipated from STARGAZE in H1 2023

VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host Disease

BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in Las Vegas, NV. Company management will also be participating in one-on-one investor meetings at the conference on Wednesday, May 11, 2022.

VectivBio to Participate at the Bank of America 2022 Healthcare Conference

Arena Pharmaceuticals and Actelion veteran brings deep industry experience as VectivBio prepares for key upcoming catalysts Arena Pharmaceuticals and Actelion veteran brings deep industry experience as VectivBio prepares for key upcoming catalysts

VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications

VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript

Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022

VectivBio Reports Full Year 2021 Financial Results and Provides Business Update

BASEL, Switzerland, March 30, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that it has entered two agreements that will strengthen the company's balance sheet, bolster the company's operations and expand apraglutide's commercial potential beyond VectivBio's core markets in the US and EU. The two agreements, together with VectivBio's cash and cash equivalents as of December 31, 2021 of $103 million, provides up to $220 million in operating capital.

VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts

-- Apraglutide well-tolerated and does not require dose-adjustment in patients with severe renal disease -- -- Results demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who are underserved by currently available therapies --

VectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF) Patients Who Have Renal Dysfunction at the 2022 American Society of Parenteral and Enteral Nutrition Conference

-- Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival in mouse models of GI acute graft-versus-host disease (aGVHD) -- -- Data support regenerative, non-immunosuppressive hypothesis for clinical evaluation; launched Phase 2 STARGAZE clinical study of apraglutide in steroid-refractory GI aGVHD following FDA clearance of the company's Investigational New Drug (IND) application --

VectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation

BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022, at 1:40 p.m. ET. Company management will also be participating in one-on-one investor meetings at the conference.

VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference

4D Molecular Therapeutics

First Watch Restaurant Group

NerdWallet

Singular Genomics Systems

PROCEPT BioRobotics Corp

The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last year.

6 Underperforming IPO Stocks To Buy On The Dip

-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022-

VectivBio Announces Third Quarter 2021 Business Update

BASEL, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a virtual fireside chat at the Credit Suisse 30th Annual Healthcare Conference on Thursday, November 11, 2021 at 9:40 a.m. ET.

VectivBio to Present at the Credit Suisse 30th Annual Healthcare Conference

-FDA clears IND Application for Apraglutide for Acute Graft-Versus-Host Disease

VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease

- Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases - - Proprietary CoMET platform aims to treat severe rare Inherited Metabolic Diseases -

VectivBio Announces Closing of Comet Therapeutics Acquisition

Company to host an R&D Day on September 21, 2021 Company to host an R&D Day on September 21, 2021

VectivBio Announces Upcoming Investor Events

Biopharma veteran enhances VectivBio's legal, regulatory and operational capabilities Biopharma veteran enhances VectivBio's legal, regulatory and operational capabilities

VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary

- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline - - VectivBio to Host R&D Day on September 21, 2021-

VectivBio to Acquire Comet Therapeutics and Host R&D Day

BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions, today published the invitation to the Extraordinary General Meeting, which will be held on Thursday, September 2, 2021, at 2:00 p.m. CEST / 8:00 a.m. EDT at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland.

VectivBio Publishes Invitation to the Extraordinary General Meeting

- Industry veterans bring decades of clinical, regulatory and commercial management expertise to VectivBio - - Nominees will stand for election at an Extraordinary General Meeting of shareholders on September 2, 2021 -

VectivBio Nominates Paul R. Carter and Murray W.

Phase 2 trial expected to begin in the first quarter of 2022 Phase 2 trial expected to begin in the first quarter of 2022

News for VectivBio Holding AG Stock (VECT)